Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients.
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index; 10 of the 14 sources its claims cite were checked for support.
Abstract
Case series of three advanced cancer patients self-administering fenbendazole.
Overview
CoChat Summary
TL;DR
This is a 3-patient case series describing self-administration of fenbendazole (FBZ) in advanced breast cancer, prostate cancer, and melanoma. The authors report complete remission in 2 patients and near-complete remission in 1 patient, but they emphasize that causality cannot be established from these uncontrolled observations.
Key findings
- Three patients with advanced malignancy (breast, prostate, melanoma) self-administered FBZ and all were reported to tolerate it without adverse effects attributable to FBZ.
- Case 1 (stage IV breast cancer): after starting FBZ 222 mg/day on November 22, 2021, CA 27.29 fell from 316 to 36.6 by July 2022; a PET scan on April 20, 2022 showed no abnormal metabolic activity, and the patient was deemed in complete remission in June 2022 and remained recurrence-free nearly 3 years later.
- Case 2 (recurrent stage IV prostate cancer): FBZ 222–444 mg/day started in December 2021 alongside androgen deprivation therapy; after 1 year lymph node involvement had fully resolved, after 2 years imaging showed significant regression with no new metastatic sites, PSA stayed undetectable for over 2 years (<0.05 ng/mL), and the patient remained in near-complete response after 26 months.
- Case 3 (BRAFV600-mutated stage IIIC melanoma): FBZ 222–444 mg/day began in mid-December 2023; Signatera dropped from 123.37 pre-FBZ to 0.38 by January 17, 2024 and to 0 by February 21, 2024, with “no evidence of disease” reported at February 2024 follow-up and recurrence-free status over 11 months.
Methods
- Case series design based on 3 patients with advanced cancer who self-administered FBZ outside a regulated clinical trial setting; the report follows the CARE checklist.
- Data came from clinical records, imaging, laboratory/tumor marker results, and follow-up ranging from 11 months to nearly 3 years.
- The analysis is descriptive, comparing pre- and post-FBZ clinical course, imaging, and biomarkers; no control group or inferential statistical analysis is reported.
Limitations
- Stated in the paper: the authors explicitly note the small sample size, retrospective nature, self-selection bias, combination with other treatments, observational design, and inability to establish a causal relationship between FBZ and remission.
- Stated in the paper: all three patients initiated FBZ on their own, without medical recommendation or prescription, and dosing/monitoring occurred outside regulated clinical settings.
- Evident from the text: outcomes are confounded by concurrent therapies (for example, hormonal therapy, radiation, and limited immunotherapy), so the independent effect of FBZ cannot be isolated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 1 Not valid · 2 Not checked · 20 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While the doses used in this study were lower than those in the case series by Chiang et al. [1] (1 g/day, three times of week), FBZ still appears to be effective.”
§ Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients > Discussion
What the sources say
- Partly supportedcites [1] sourceExperimental — accuracy not yet measured
Section 2.2.2 reports reduced tumor growth after FBZ at 1 mg per mouse every other day in a lung-cancer xenograft study. That supports possible anti-tumor activity, but the paper does not establish effectiveness at the lower doses used in the citing authors’ human cases or compare those doses with Chiang et al.’s case series. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“FBZ has shown potential in both in vitro and in vivo models of cancer, as evidenced by studies such as those conducted by Song et al. [2].”
§ Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients > Background
What the sources say
- Partly supportedcites Song et al. [2] sourceExperimental — accuracy not yet measured
The sections on cancer cells and animal tumor models report fenbendazole’s effects in vitro and reduced tumor weight in mice, supporting its potential in both types of model. However, this source is a review reporting those studies, not an original experimental study conducted by “Song et al.”; it also reports animal models in which fenbendazole had no effect. (LLM, conf=0.86)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Beyond targeting primary cancer cells, benzimidazoles, including FBZ, have been shown to affect cancer stem cells [2, 3].”
§ Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients > Discussion
What the sources say
- Partly supportedcites [2] sourceExperimental — accuracy not yet measured
The antitumorigenic-effects section reports that benzimidazole anthelmintics inhibited stemness and reduced stem-like cell subpopulations. The cited stemness finding concerns flubendazole, however; the passages about fenbendazole (FBZ) do not establish an effect on cancer stem cells. The indexed copy provides no page number for these passages. (LLM, conf=0.85)
- Could not verifycites [3] sourceExperimental — accuracy not yet measured
The Introduction and Discussion (page numbers unavailable) describe benzimazole effects on cancer cells, including fenbendazole-treated colorectal cancer cell lines, but do not identify those cells as cancer stem cells. Searches for “cancer stem cells” and stemness or sphere formation found no passage addressing an effect on cancer stem cells. (LLM, conf=0.73)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Preclinical studies suggest that FBZ exerts its anticancer effects through a wide variety of mechanisms.”
§ Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients > Abstract > Background
What the sources say
- Supportedcites [2] source
The section on antitumorigenic effects in cancer cells (page not supplied) reports that fenbendazole inhibits PI3K/AKT and RAF/MEK/ERK signaling in KRAS-mutant lung cancer cells and describes other anticancer effects of benzimidazole anthelmintics. It also notes that fenbendazole’s effects vary by cell type, consistent with the claim’s cautious wording about preclinical studies. (LLM, conf=0.88)
- Supportedcites [3] source
The Discussion (page unavailable) reports that fenbendazole caused cell-cycle arrest and apoptosis in two colorectal cancer cell lines, with different pathways implicated in each. It also discusses possible contributions from autophagy and ferroptosis while identifying apoptosis as the primary cell-death pathway. This supports the citing sentence’s hedged description of multiple preclinical mechanisms. (LLM, conf=0.90)
- Could not verifycites [4] sourceExperimental — accuracy not yet measured
The Discussion addresses primary androgen-deprivation therapy for clinically localized prostate cancer, not preclinical anticancer effects of FBZ. Searches for FBZ, fenbendazole, and anticancer mechanisms found no passage addressing the claim in our copy. (LLM, conf=0.77)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“To our knowledge, this is only the second case series documenting such outcomes after Stanford University Medical Center research group led by Chiang et al. [1] provided valuable insights into the potential repurposing of FBZ in cancer treatment.”
§ Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients > Discussion
What the sources say
- Could not verifycites [1] sourceExperimental — accuracy not yet measured
The paper’s §2.2 (FBZ; page unavailable) discusses fenbendazole’s preclinical effects, and its Clinical Evidence section describes case reports involving mebendazole, not a fenbendazole case series. Searches for Chiang, Stanford, and a fenbendazole case series found no passage establishing the claimed first series or the ‘second case series’ count. (LLM, conf=0.76)
hedgedn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
13 more claims
Create a free account to see all 28 claims and every source verdict.
- It may state two separate claims as one. 6
- The quote only partly states this claim. 2
- Probably not a substantial claim. 2
Citations
Cites
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636 · cited 1×
“Moreover, combined treatments with FBZ in the cases presented here generally do not lead to complete remission when used alone or in combination with other therapies [8, 9].”
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Bai, R.-Y., Staedtke, V., Aprhys, C. M., Gallia, G. L., & Riggins, G. J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor077 · Cited by 201 · cited 1×
“In other words, these fi ndings are consistent with the anticancer activity of FBZ observed in in vitro and in vivo studies [10 – 12].”
(2002) · PubMed · Cited by 177
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130 · cited 2×
“Beyond targeting primary cancer cells, benzimidazoles, including FBZ, have been shown to affect cancer stem cells [2, 3].”
Dogra, N., Kumar, A., & Mukhopadhyay, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-30158-6 · Cited by 128
Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer
Potosky, A. L., Haque, R., Cassidy-Bushrow, A. E., Ulcickas Yood, M., Jiang, M., Tsai, H.-T., Luta, G., Keating, N. L., Smith, M. R., & Van Den Eeden, S. K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.5782 · Cited by 75
Florio, R., Veschi, S., di Giacomo, V., Pagotto, S., Carradori, S., Verginelli, F., Cirilli, R., Casulli, A., Grassadonia, A., Tinari, N., et al. (2019) · Cancers · doi:10.3390/cancers11122042 · Cited by 55 · cited 1×
“In other words, these fi ndings are consistent with the anticancer activity of FBZ observed in in vitro and in vivo studies [10 – 12].”
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55 · cited 2×
“Beyond targeting primary cancer cells, benzimidazoles, including FBZ, have been shown to affect cancer stem cells [2, 3].”
Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells
Park, D., Lee, J.-H., & Yoon, S.-P. (2022) · The Korean Journal of Physiology & Pharmacology · doi:10.4196/kjpp.2022.26.5.377 · Cited by 23
Mukherjee, P., Maurer, J., Stopka, S. A., Greenwood, B. P., Aristizabal‐Henao, J. J., Karmacharya, S., Chimento, A., Ta, N. L., Lee, D. C., Duraj, T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102845 · Cited by 8
Cited by
Drug Repurposing in Veterinary Oncology: Myth or Reality?
Ciccarelli, S., Perrone, C., Cavalera, M. A., & Giuliano, A. (2025) · Veterinary Sciences · doi:10.3390/vetsci12111067 · Cited by 5
“Some human case reports suggest potential for complete or near-complete remission in advanced cancer cases when combined with other therapies with good tolerability [23–25].”
Metadata
- Authors
- Makis, W., Baghli, I., & Martinez, P.
- Affiliations
- Alberta Health Services (CA)
- Venue
- Case Reports in Oncology
- Publisher
- S. Karger AG
- Published
- 2025-05-26
- Volume
- 18
- Issue
- 1
- Pages
- 856-863
- ISSN
- 1662-6575 (ISSN-L)
- PMC
- PMC12215191
- OpenAlex
- W4410772980
- Semantic Scholar
- d2257a5a61d4e99f9fc2b9753db62dd60bfe3701
- Cited by
- 1
- References
- 9
- Citations by year
- 2025: 1
- FWCI
- 0.30
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Case Reports in Oncology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- fenbendazole, anticancer drug repurposing, antiparasitic drugs, self-administration, metastatic cancer, breast cancer, prostate cancer, melanoma, complete remission, tumor regression, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients. https://app.cochat.ai/papers/10.1159/000546362
- The paper
- Makis, W., Baghli, I., & Martinez, P. (2025). Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients. Case Reports in Oncology. https://doi.org/10.1159/000546362
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.